But understanding where the protocol goes helps you anticipate concentration changes, syringe upgrades, and the practical logistics of higher doses before you reach them
Key Takeaways: Section 15 PBM formulary co-placement of originator and biosimilar on the same preferred tier is the primary mechanism by which biosimilar savings potential is unrealized in commercial markets
10.1177/23259671241297157 42 RyanM.MegyeriS.NufferW.TrujilloJ
While neither Tirzepatide nor Semaglutide are known to cause direct liver or kidney damage , they can lead to dehydration or enzyme changes that may stress these organs, especially in patients who already have liver or kidney disease
When to see a doctor: if you notice bald patches, an irritated scalp, or a clear pattern that remains after 12 months
Discontinuation due to side effects was slightly higher at the higher doses, up to 5.1%